These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21098317)

  • 21. Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy.
    Esquerdo G; Doménech M; López P; Pedro C; Villadiego K; Constenla M; Sánchez-Rovira P; Gasquet JA; Rodríguez CA;
    Tumori; 2014; 100(2):225-31. PubMed ID: 24852870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia.
    Charu V; Saidman B; Ben-Jacob A; Justice GR; Maniam AS; Tomita D; Rossi G; Rearden T; Glaspy J
    Oncologist; 2007 Oct; 12(10):1253-63. PubMed ID: 17962619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents.
    Silver MR; Geronemus R; Krause M; Chen CY; Kewalramani R; Stehman-Breen C
    Curr Med Res Opin; 2009 Jan; 25(1):123-31. PubMed ID: 19210145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly.
    Senecal FM; Yee L; Gabrail N; Charu V; Tomita D; Rossi G; Schwartzberg L
    Clin Breast Cancer; 2005 Dec; 6(5):446-54. PubMed ID: 16381629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.
    Vansteenkiste J; Pirker R; Massuti B; Barata F; Font A; Fiegl M; Siena S; Gateley J; Tomita D; Colowick AB; Musil J;
    J Natl Cancer Inst; 2002 Aug; 94(16):1211-20. PubMed ID: 12189224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia.
    Hernandez E; Ganly P; Charu V; Dibenedetto J; Tomita D; Lillie T; Taylor K;
    Curr Med Res Opin; 2009 Sep; 25(9):2109-20. PubMed ID: 19601709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study.
    Kotasek D; Steger G; Faught W; Underhill C; Poulsen E; Colowick AB; Rossi G; Mackey J;
    Eur J Cancer; 2003 Sep; 39(14):2026-34. PubMed ID: 12957457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
    Boccia RV; Henry DH; Belton L; Bohac C; Ghazal HH
    Cancer Med; 2016 Dec; 5(12):3445-3453. PubMed ID: 27882724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
    Macdougall IC; Walker R; Provenzano R; de Alvaro F; Locay HR; Nader PC; Locatelli F; Dougherty FC; Beyer U;
    Clin J Am Soc Nephrol; 2008 Mar; 3(2):337-47. PubMed ID: 18287255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for using darbepoetin alfa in patients with chemotherapy-induced anemia.
    Bloomfield M; Jaresko G; Zarek J; Dozier N
    Pharmacotherapy; 2003 Dec; 23(12 Pt 2):110S-118S. PubMed ID: 14695000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia.
    Boccia R; Malik IA; Raja V; Kahanic S; Liu R; Lillie T; Tomita D; Clowney B; Silberstein P
    Oncologist; 2006 Apr; 11(4):409-17. PubMed ID: 16614237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease.
    Joy MS; Candiani C; Vaillancourt BA; Chin H; Hogan SL; Falk RJ
    Pharmacotherapy; 2007 May; 27(5):734-44. PubMed ID: 17461709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J; Reeves T; Wallace J
    Oncologist; 2004; 9(4):451-8. PubMed ID: 15266098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
    Glaspy JA; Jadeja JS; Justice G; Fleishman A; Rossi G; Colowick AB
    Cancer; 2003 Mar; 97(5):1312-20. PubMed ID: 12599240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
    Feriani M; De Meester JM; McMahon LP; Rottembourg JB; Bridges I; Farouk M; Pronai W
    BMC Nephrol; 2011 Mar; 12():13. PubMed ID: 21435267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
    Hesketh PJ; Arena F; Patel D; Austin M; D'Avirro P; Rossi G; Colowick A; Schwartzberg L; Bertoli LF; Cole JT; Demetri G; Dessypris E; Dobbs T; Eisenberg P; Fleischman R; Hall J; Hoffman PC; Laber DA; Leonard J; Lester EP; McCachren S; McMeekin S; Meza L; Miller DS; Nand S; Oliff I; Paroly W; Pawl L; Perez A; Raftopoulos H; Rigas J; Rowland K; Scullin DC; Tezcan H; Waples J; Ward J; Yee LK
    Cancer; 2004 Feb; 100(4):859-68. PubMed ID: 14770445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
    Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
    Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia.
    Ray-Coquard I; Laplaige P; Vey N; Asselain B; Urbieta M
    Curr Med Res Opin; 2010 Nov; 26(11):2653-60. PubMed ID: 20932223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.